title: Single-dose fentanyl sublingual spray for breakthrough cancer pain.
abstract: Breakthrough cancer pain (BTCP) is defined as a transient exacerbation of pain that arises in patients with otherwise controlled persistent pain. BTCP typically has a rapid onset and relatively short duration, but it causes a significant amount of physical and psychological distress for patients. Several rapid-onset fentanyl formulations have been introduced in the USA to replace traditional oral opioids for the treatment of BTCP: a transmucosal lozenge, a sublingual orally disintegrating tablet, a buccal tablet, a buccal soluble film, a pectin nasal spray and, the newest formulation to enter the market, a sublingual spray. This article reviews the six rapid-onset formulations of fentanyl approved in the USA for the management of BTCP with emphasis on describing the published literature on fentanyl sublingual spray. The different fentanyl formulations vary in pharmacokinetic properties and ease of use, but all have a rapid onset and a relatively short duration of analgesia. Fentanyl sublingual spray has demonstrated absorption within 5 minutes of administration, with fentanyl plasma concentrations increasing over the first 30 minutes and remaining elevated for 60-90 minutes in pharmacokinetic studies in healthy subjects. Fentanyl sublingual spray shows linear dose proportionality, and changes in the temperature or acidity of the oral cavity do not alter its pharmacokinetic properties. In patients with BTCP, statistically significant pain relief is measurable at 5 minutes after administration of fentanyl sublingual spray, when compared with placebo, with significant pain relief lasting at least 60 minutes after administration. Adverse events are typical of opioid treatment and are considered mild to moderate in intensity. In summary, fentanyl sublingual spray provides rapid onset of analgesia and is a tolerable and effective treatment for BTCP.
authors.affiliation: Comprehensive Pain Care PC, Marietta, GA, USA.
authors.forename: Donald R
authors.initials: DR
authors.lastname: Taylor
keywords: breakthrough pain; cancer; fentanyl; fentanyl sublingual spray; rapid-onset opioid; sublingual
references.citation: Value Health. 2005 Nov-Dec;8 Suppl 1:S9-S24
references.pmid: 16336491
references.citation: Br J Nurs. 2011 Jul 15-28;20(13):803-4, 806-7
references.pmid: 21841688
references.citation: Pain. 2010 Dec;151(3):617-624
references.pmid: 20800358
references.citation: Ann Oncol. 2010 Jun;21(6):1308-1314
references.pmid: 19940014
references.citation: Health Qual Life Outcomes. 2004 Feb 26;2:12
references.pmid: 14987333
references.citation: J Pharm Sci. 1992 Jan;81(1):1-10
references.pmid: 1619560
references.citation: J Opioid Manag. 2011 Jan-Feb;7(1):69-79
references.pmid: 21434586
references.citation: AAPS J. 2008 Jun;10(2):261-7
references.pmid: 18459057
references.citation: Clin Drug Investig. 2011;31(9):605-18
references.pmid: 21819159
references.citation: Curr Med Res Opin. 2009 Dec;25(12):2877-85
references.pmid: 19814586
references.citation: Clin Pharmacokinet. 2002;41(9):661-80
references.pmid: 12126458
references.citation: Pain Physician. 2012 Jul;15(3 Suppl):ES39-58
references.pmid: 22786461
references.citation: Clin Pharmacol Ther. 1988 Sep;44(3):335-42
references.pmid: 2458208
references.citation: Expert Rev Neurother. 2011 Aug;11(8):1197-216
references.pmid: 21797660
references.citation: J Pain Symptom Manage. 2000 Aug;20(2):87-92
references.pmid: 10989246
references.citation: Lancet Oncol. 2012 Feb;13(2):e58-68
references.pmid: 22300860
references.citation: Gen Dent. 2011 May-Jun;59(3):168-70
references.pmid: 21903538
references.citation: Clin J Pain. 2006 Nov-Dec;22(9):805-11
references.pmid: 17057563
references.citation: Pain. 1990 Jun;41(3):273-281
references.pmid: 1697056
references.citation: Ann Oncol. 2011 Sep;22 Suppl 6:vi69-77
references.pmid: 21908508
references.citation: Clin Ther. 2013 Mar;35(3):236-43
references.pmid: 23497761
references.citation: Pain. 1999 May;81(1-2):129-34
references.pmid: 10353500
references.citation: J Pain Symptom Manage. 2011 Jan;41(1):116-25
references.pmid: 20580202
references.citation: Int J Pharm. 1999 Dec 10;192(2):139-46
references.pmid: 10567745
references.citation: J Pharm Pharm Sci. 1998 Jan-Apr;1(1):15-30
references.pmid: 10942969
references.citation: Clin Drug Investig. 2013 Jun;33(6):391-400
references.pmid: 23605506
references.citation: J Natl Compr Canc Netw. 2010 Sep;8(9):1046-86
references.pmid: 20876544
references.citation: Curr Med Res Opin. 2012 May;28(5):859-70
references.pmid: 22480131
references.citation: J Pain Symptom Manage. 2010 Nov;40(5):747-60
references.pmid: 20594801
references.citation: Risk Manag Healthc Policy. 2011;4:97-105
references.pmid: 22312232
references.citation: Eur J Pain. 2009 Apr;13(4):331-8
references.pmid: 18707904
references.citation: Acta Anaesthesiol Scand. 2012 Apr;56(4):407-19
references.pmid: 22260169
references.citation: Curr Med Res Opin. 2012 Nov;28(11):1781-90
references.pmid: 23020252
references.citation: Expert Opin Pharmacother. 2012 Apr;13(6):873-8
references.pmid: 22424558
references.citation: J Pain Res. 2012;5:559-66
references.pmid: 23204865
references.citation: Curr Med Res Opin. 2011 Apr;27(4):751-60
references.pmid: 21288055
references.citation: Palliat Med. 2003 Mar;17(2):219-21
references.pmid: 12701855
references.citation: Drugs. 2012 Jan 22;72(2):181-90
references.pmid: 22233484
references.citation: J Support Oncol. 2010 Jul-Aug;8(4):184-90
references.pmid: 20822038
references.citation: Curr Opin Support Palliat Care. 2011 Mar;5(1):8-14
references.pmid: 21325998
references.citation: J Natl Cancer Inst. 1998 Apr 15;90(8):611-6
references.pmid: 9554444
references.citation: Br J Nurs. 2011 May 27-Jun 9;20(10):S14, S16-9
references.pmid: 21647006